| 11/16/2026 7:51 PM | Ikarian Capital, LLC (1778253) Filed by Quince Therapeutics (1662774) Subject | Form SCHEDULE 13G/A | |
| 11/16/2026 3:20 PM | Quince Therapeutics (1662774) Subject SILVERARC CAPITAL MANAGEMENT, LLC (1816307) Filed by | Form SCHEDULE 13G/A | |
| 11/16/2026 11:53 AM | Quince Therapeutics (1662774) Subject Squadron Capital Management LLC (2050709) Filed by | Form SCHEDULE 13G/A | |
| 11/16/2026 5:04 AM | BALYASNY ASSET MANAGEMENT L.P. (1218710) Filed by Quince Therapeutics (1662774) Subject | Form SCHEDULE 13G/A | |
| 11/13/2026 6:37 PM | Quince Therapeutics (1662774) Subject SILVERARC CAPITAL MANAGEMENT, LLC (1816307) Filed by | Form SCHEDULE 13G | |
| 11/12/2026 3:10 PM | Quince Therapeutics (1662774) Issuer Militello John (1662170) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/12/2026 3:10 PM | Bonuccelli Catherine M. (2159407) Reporting Quince Therapeutics (1662774) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/12/2026 3:10 PM | Quince Therapeutics (1662774) Issuer PATTERSON LEONE D (1233539) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/12/2026 3:10 PM | Quince Therapeutics (1662774) Issuer Valentine James Elwood (2159117) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/12/2026 3:10 PM | Quince Therapeutics (1662774) Issuer Wise John Drayton (1930805) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/05/2026 2:42 PM | Quince Therapeutics (1662774) Subject Lamond David (1770790) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Get the Latest News and Ratings for QNCX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Quince Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 10/21/2026 4:15 PM | Quince Therapeutics (1662774) Subject Thye Dirk (1638945) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 10/19/2026 3:10 PM | Quince Therapeutics (1662774) Issuer PATTERSON LEONE D (1233539) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 10/19/2026 3:11 PM | Fandrick Keith R. (2159394) Reporting Quince Therapeutics (1662774) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 10/19/2026 3:12 PM | Quince Therapeutics (1662774) Issuer Militello John (1662170) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 10/19/2026 3:14 PM | Quince Therapeutics (1662774) Issuer Wise John Drayton (1930805) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 10/19/2026 3:15 PM | Quince Therapeutics (1662774) Issuer Valentine James Elwood (2159117) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 10/19/2026 3:16 PM | Bonuccelli Catherine M. (2159407) Reporting Quince Therapeutics (1662774) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 10/19/2026 7:49 AM | Quince Therapeutics (1662774) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/14/2026 3:38 PM | Foresite Capital Fund VI LP (1932516) Filed by Quince Therapeutics (1662774) Subject | Form SCHEDULE 13G | |
| 10/14/2026 3:00 PM | Quince Therapeutics (1662774) Subject PERCEPTIVE ADVISORS LLC (1224962) Filed by | Form SCHEDULE 13G | |
| 10/09/2026 6:59 AM | Quince Therapeutics (1662774) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/08/2026 4:26 PM | Quince Therapeutics (1662774) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 10/06/2026 3:57 PM | Quince Therapeutics (1662774) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/02/2026 6:30 AM | Quince Therapeutics (1662774) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/02/2026 6:31 AM | Quince Therapeutics (1662774) Filer | Form DEFA14A | |
| 09/14/2026 3:30 PM | Quince Therapeutics (1662774) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/04/2026 7:30 AM | Quince Therapeutics (1662774) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/27/2026 3:30 PM | Quince Therapeutics (1662774) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/25/2026 7:30 AM | Quince Therapeutics (1662774) Filer | Form DEF 14A | |
| 08/24/2026 11:15 PM | Quince Therapeutics (1662774) Filer | Form EFFECT | |
| 08/17/2026 5:01 AM | Quince Therapeutics (1662774) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/14/2026 8:20 PM | Ikarian Capital, LLC (1778253) Filed by Quince Therapeutics (1662774) Subject | Form SCHEDULE 13G | |
| 08/14/2026 1:05 PM | Cormorant Asset Management, LP (1583977) Filed by Quince Therapeutics (1662774) Subject | Form SCHEDULE 13G | |
| 08/14/2026 7:21 AM | Quince Therapeutics (1662774) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/14/2026 5:07 AM | BALYASNY ASSET MANAGEMENT L.P. (1218710) Filed by Quince Therapeutics (1662774) Subject | Form SCHEDULE 13G | |
| 08/05/2026 5:30 AM | Quince Therapeutics (1662774) Filer | Form S-3/A | |
| 08/04/2026 2:06 PM | Quince Therapeutics (1662774) Subject Squadron Capital Management LLC (2050709) Filed by | Form SCHEDULE 13G | |
| 07/31/2026 3:45 PM | Quince Therapeutics (1662774) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 07/31/2026 3:48 PM | Quince Therapeutics (1662774) Filer | Form PRE 14A | |
| 07/31/2026 3:50 PM | Quince Therapeutics (1662774) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
A $247 tool for $7 (Ad) Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install.
The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years. See the Instant Scanner in action and claim the $7 Black Friday deal today. |
| 07/30/2026 5:02 AM | Quince Therapeutics (1662774) Filer | Form 8-K/A | |
| 06/26/2026 3:31 PM | Quince Therapeutics (1662774) Filer | Form 8-K/A | |
| 06/26/2026 8:18 AM | Quince Therapeutics (1662774) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/15/2026 4:57 PM | Lamond David (1770790) Reporting Quince Therapeutics (1662774) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/15/2026 4:51 PM | Quince Therapeutics (1662774) Issuer Senner Christopher J. (1648367) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/11/2026 4:28 PM | Quince Therapeutics (1662774) Issuer Roberts Brigette (1346566) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 06/11/2026 4:30 PM | Quince Therapeutics (1662774) Issuer Roberts Brigette (1346566) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/11/2026 4:06 PM | Quince Therapeutics (1662774) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/11/2026 11:01 AM | Quince Therapeutics (1662774) Filer | Form D Notice of Exempt Offering of Securities | |
| 06/11/2026 11:02 AM | Quince Therapeutics (1662774) Filer | Form D Notice of Exempt Offering of Securities | |
| 06/10/2026 3:38 PM | INTEGRATED CORE STRATEGIES (0) US Quince Therapeutics (1662774) Subject | Form SCHEDULE 13G | |
| 05/21/2026 4:06 PM | Quince Therapeutics (1662774) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/18/2026 3:20 PM | Quince Therapeutics (1662774) Filer | Form 8-K/A | |
| 05/18/2026 8:33 AM | Quince Therapeutics (1662774) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/11/2026 4:09 PM | Quince Therapeutics (1662774) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 04/28/2026 3:30 PM | Quince Therapeutics (1662774) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/27/2026 3:39 PM | Quince Therapeutics (1662774) Filer | Form DEF 14A | |
| 04/27/2026 3:41 PM | Quince Therapeutics (1662774) Filer | Form DEFA14A | |
| 04/27/2026 3:42 PM | Quince Therapeutics (1662774) Filer | Form ARS | |
| 04/22/2026 3:30 PM | Quince Therapeutics (1662774) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/17/2026 4:25 PM | Quince Therapeutics (1662774) Filer | Form PRE 14A | |
| 04/17/2026 3:53 PM | Quince Therapeutics (1662774) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 04/10/2026 3:35 PM | Quince Therapeutics (1662774) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 04/09/2026 8:23 AM | Quince Therapeutics (1662774) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/01/2026 3:30 PM | Quince Therapeutics (1662774) Filer | Form NT 10-K | |
| 03/30/2026 7:35 AM | Quince Therapeutics (1662774) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/20/2026 3:45 PM | Quince Therapeutics (1662774) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/05/2026 4:52 PM | GROUP ONE TRADING LLC (932540) Filed by Quince Therapeutics (1662774) Subject | Form SCHEDULE 13G | |
| 02/12/2026 5:06 AM | Quince Therapeutics (1662774) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/23/2026 7:25 PM | Quince Therapeutics (1662774) Issuer Thye Dirk (1638945) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/23/2026 7:05 PM | Hannah Brendan (1929422) Reporting Quince Therapeutics (1662774) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/23/2026 7:07 PM | Quince Therapeutics (1662774) Issuer Ryan Charles S. (1624830) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/21/2026 5:14 PM | Quince Therapeutics (1662774) Issuer Senner Christopher J. (1648367) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/21/2026 4:59 PM | Bray June (1845487) Reporting Quince Therapeutics (1662774) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/21/2026 5:05 PM | Lamond David (1770790) Reporting Quince Therapeutics (1662774) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/21/2026 5:10 PM | McLoughlin Margaret (1770823) Reporting Quince Therapeutics (1662774) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/29/2025 4:34 PM | Benatti Luca (1613842) Reporting Quince Therapeutics (1662774) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/29/2025 4:36 PM | Benatti Luca (1613842) Reporting Quince Therapeutics (1662774) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/29/2025 4:51 PM | Benatti Luca (1613842) Reporting Quince Therapeutics (1662774) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/12/2025 4:07 PM | Quince Therapeutics (1662774) Issuer Thye Dirk (1638945) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/08/2025 7:12 AM | Hannah Brendan (1929422) Reporting Quince Therapeutics (1662774) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |